Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
BIDU-SW
09888
5
JD HEALTH
06618
| (Q9)Sep 30, 2025 | (Q6)Jun 30, 2025 | (Q1)Mar 31, 2025 | (FY)Dec 31, 2024 | (Q9)Sep 30, 2024 | (Q6)Jun 30, 2024 | (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q9)Sep 30, 2023 | (Q6)Jun 30, 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Turnover | -4.15%312.5B | -8.45%207.61B | -4.14%106.85B | 0.94%420.51B | 6.26%326.02B | 18.07%226.77B | 14.08%111.47B | -1.33%416.61B | -1.39%306.82B | -5.09%192.06B |
| Operating income | -4.15%312.5B | -8.45%207.61B | -4.14%106.85B | 0.94%420.51B | 6.26%326.02B | 18.07%226.77B | 14.08%111.47B | -1.33%416.61B | -1.39%306.82B | -5.09%192.06B |
| Operating expenses | -0.51%-149.26B | 6.65%-48.46B | 3.98%-148.5B | -4.61%-51.91B | -9.15%-154.65B | |||||
| Gross profit | -8.04%163.25B | -1.95%58.39B | 16.66%177.53B | 23.85%59.55B | -10.20%152.17B | |||||
| Selling expenses | -7.05%-2.78B | -2.07%-5.33B | -6.11%-938M | -1.72%-11.14B | 1.11%-2.59B | -4.63%-5.22B | -1.14%-884M | -4.62%-10.95B | -5.60%-2.62B | -13.98%-4.99B |
| Administrative expenses | -7.29%-5.4B | ---- | -1.60%-1.65B | ---- | -5.40%-5.03B | ---- | -22.51%-1.62B | ---- | -16.41%-4.78B | ---- |
| Research and development expenses | 9.00%-1.11B | ---- | 4.46%-321M | ---- | -2.78%-1.22B | ---- | 4.27%-336M | ---- | -46.43%-1.19B | ---- |
| Profit from asset sales | -72.00%7M | ---- | -33.33%2M | ---- | 1,350.00%25M | ---- | 50.00%3M | ---- | -114.29%-2M | ---- |
| Depreciation and amortization | ---- | -4.69%-39.32B | ---- | -8.21%-74.61B | ---- | -11.31%-37.56B | ---- | -9.70%-68.95B | ---- | -14.34%-33.74B |
| Revaluation surplus | -47.45%515M | ---- | 251.79%197M | ---- | 102.90%980M | ---- | -89.87%56M | ---- | 222.00%483M | ---- |
| -Changes in the fair value of other assets | -47.45%515M | ---- | 251.79%197M | ---- | 102.90%980M | ---- | -89.87%56M | ---- | 222.00%483M | ---- |
| Impairment and provision | -64.44%-74M | -73.53%-59M | 116.00%4M | -124.52%-8.08B | 85.89%-45M | 88.67%-34M | -2,400.00%-25M | -440.09%-3.6B | -184.82%-319M | -191.26%-300M |
| -Other impairment is provision | -64.44%-74M | -73.53%-59M | 116.00%4M | -124.52%-8.08B | 85.89%-45M | 88.67%-34M | -2,400.00%-25M | -440.09%-3.6B | -184.82%-319M | -191.26%-300M |
| Special items of operating profit | -159.09%-943M | 14.93%-57.9B | -197.56%-600M | 13.69%-121.7B | -60.01%1.6B | -12.69%-68.06B | -36.79%615M | -3.58%-141.01B | 1.35%3.99B | 2.72%-60.39B |
| Operating profit | -10.23%139.88B | -9.89%95.1B | -4.22%50.08B | 10.09%184.71B | 16.36%155.83B | 25.24%105.54B | 20.76%52.29B | -13.22%167.77B | -11.90%133.92B | -13.18%84.27B |
| Financing income | ---- | -4.47%2.48B | ---- | -4.64%4.58B | ---- | 12.91%2.6B | ---- | 61.24%4.81B | ---- | 106.28%2.3B |
| Financing cost | 67.25%-467M | 5.74%-3.14B | -150.00%-155M | -13.86%-6.1B | -91.67%-1.43B | -18.86%-3.33B | 532.65%310M | 11.17%-5.35B | 65.75%-744M | 9.82%-2.8B |
| Share of profits of associates | ---- | -21.39%316M | ---- | -10.94%757M | ---- | -4.96%402M | ---- | 28.21%850M | ---- | 40.07%423M |
| Share of profit from joint venture company | ---- | -812.50%-1.14B | ---- | -0.19%1.08B | ---- | -62.26%160M | ---- | -13.38%1.08B | ---- | -24.69%424M |
| Special items of earning before tax | ---- | 157.32%1.04B | ---- | 29.45%4.95B | ---- | -79.87%403M | ---- | 48.12%3.82B | ---- | 2.19%2B |
| Adjustment items of earning before tax | -1,942.86%-286M | ---- | -58.33%-95M | ---- | 93.52%-14M | ---- | 23.08%-60M | ---- | -61.19%-216M | ---- |
| Earning before tax | -9.88%139.13B | -10.51%94.66B | -5.15%49.83B | 9.83%189.98B | 16.12%154.39B | 22.11%105.78B | 21.42%52.54B | -11.19%172.97B | -11.18%132.96B | -11.52%86.62B |
| Tax | 1.68%-37.07B | 3.71%-25.07B | -3.28%-13.23B | -6.36%-51.99B | -6.81%-37.7B | -13.80%-26.03B | -14.79%-12.81B | 7.93%-48.88B | 13.78%-35.3B | 12.07%-22.87B |
| After-tax profit from continuing operations | -12.53%102.06B | -12.73%69.59B | -7.87%36.6B | 11.20%137.98B | 19.48%116.68B | 25.09%79.75B | 23.72%39.73B | -12.41%124.09B | -10.21%97.66B | -11.32%63.75B |
| Earning after tax | -12.53%102.06B | -12.73%69.59B | -7.87%36.6B | 11.20%137.98B | 19.48%116.68B | 25.09%79.75B | 23.72%39.73B | -12.41%124.09B | -10.21%97.66B | -11.32%63.75B |
| Minority profit | 260.00%90M | 328.57%60M | 442.86%38M | -81.38%46M | 78.57%25M | 207.69%14M | 275.00%7M | 1,173.91%247M | 240.00%14M | -225.00%-13M |
| Profit attributable to shareholders | -12.59%101.97B | -12.79%69.53B | -7.95%36.56B | 11.38%137.94B | 19.47%116.66B | 25.05%79.73B | 23.69%39.72B | -12.60%123.84B | -10.23%97.65B | -11.30%63.76B |
| Basic earnings per share | -12.65%2.14 | -13.10%1.46 | -8.33%0.77 | 11.54%2.9 | 19.51%2.45 | 25.37%1.68 | 23.53%0.84 | -14.19%2.6 | -12.39%2.05 | -14.65%1.34 |
| Diluted earnings per share | -12.65%2.14 | -13.10%1.46 | -8.33%0.77 | 11.54%2.9 | 19.51%2.45 | 25.37%1.68 | 23.53%0.84 | -14.19%2.6 | -12.39%2.05 | -14.65%1.34 |
| Currency Unit | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY |
| Accounting Standards | CAS (2007) | IAS and HKAS | CAS (2007) | IAS and HKAS | CAS (2007) | IAS and HKAS | CAS (2007) | IAS and HKAS | CAS (2007) | IAS and HKAS |
| Audit Opinions | -- | -- | -- | Unqualified Opinion | -- | -- | -- | Unqualified Opinion | -- | -- |
| Auditor | -- | -- | -- | Ernst & Young Huaming (Special General Partnership), Ernst & Young | -- | -- | -- | Ernst & Young Huaming (Special General Partnership), Ernst & Young | -- | -- |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.